Ultragenyx Pharmaceutical Inc

NASDAQ:RAREUnited States

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Contact Information

Headquarters

60 Leveroni CtNOVATO, CA, United States 94949-5746

Phone

415-483-8800

Fax

415-483-8810

Executives

Independent Chairman of the Board

Daniel Welch

President, Chief Executive Officer, Director

Emil Kakkis

Chief Financial Officer, Executive Vice President, Corporate Strategy

Howard Horn

Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations

Dennis Huang

Executive Vice President, Chief Legal Officer, General Counsel

Karah Parschauer